🔎 Trials Near Me

Utama › Karsinoma Neuroendokrin › Maryland

Kajian klinikal Karsinoma Neuroendokrin di Maryland

6 kajian untuk Karsinoma Neuroendokrin sedang mencari peserta di lokasi di Maryland.

Teks kajian rasmi (Bahasa Inggeris)

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 2
Umur 18 hingga 120 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT06406465

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1
Umur 18 hingga 120 · Semua jantina · Dikemas kini 2 Okt 2026 · NCT07509034

Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaKajian pemerhatian
Umur 18 hingga 120 · Semua jantina · Dikemas kini 24 Sep 2026 · NCT05237934

Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors

  • United Theranostics, Glen Burnie
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 22 Sep 2026 · NCT07278479

A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)

  • Sidney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 15 Jul 2026 · NCT05652686

A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors

  • National Institutes of Health Clinical Center, Bethesda
Mengambil pesertaFasa 1
Umur 18 hingga 120 · Semua jantina · Dikemas kini 15 Jun 2026 · NCT06041516

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.